(HART) to Present at East Coast IDEAS Investor Conference

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces that David Green, Chief Executive Officer, will present at the 2014 East Coast IDEAS Investor Conference at the Metro Meeting Center in Boston, MA. Mr. Green is scheduled to present on Thursday, June 5 at 3:50 pm in Presenting Room 1.

Mr. Green will provide an overview of the company, recent business developments and growth strategy.

The presentation will be webcast and available at the following link: http://www.wsw.com/webcast/threepa13/hart.

IDEAS Investor Conferences are sponsored by and directly for the benefit of regional investment communities. Attendees include mutual fund managers, hedge fund managers, family offices, high-net-worth investors and other accredited investors. For more information, please visit http://www.threepartadvisors.com/#!east-coast-ideas/crux.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART’s products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.